Clostridium Difficile Infection Clinical Trial
— FMTOfficial title:
Fecal Microbiota Transplant National Registry
NCT number | NCT03325855 |
Other study ID # | AmericanGA |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | September 20, 2017 |
Est. completion date | August 2027 |
A national data registry of patients receiving fecal microbiota transplantation (FMT) or other gut-related-microbiota products designed to prospectively assess short and long-term safety and effectiveness
Status | Recruiting |
Enrollment | 4000 |
Est. completion date | August 2027 |
Est. primary completion date | August 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Recipient Inclusion Criteria - Ability to give informed consent - Receiving FMT or other gut-related microbiota product within 90 days after providing consent - Access to internet and/or telephone - Donor Inclusion - Ability to give informed consent - Providing stool sample for FMT Exclusion Criteria: - Incarceration |
Country | Name | City | State |
---|---|---|---|
Canada | University of Alberta | Edmonton | Alberta |
United States | St. Joseph Mercy Hospital | Ann Arbor | Michigan |
United States | University of Michigan | Ann Arbor | Michigan |
United States | Johns Hopkins University School of Medicine | Baltimore | Maryland |
United States | American Gastroenterological Association | Bethesda | Maryland |
United States | Boston Children's Hospital | Boston | Massachusetts |
United States | Brigham and Women's Hospital | Boston | Massachusetts |
United States | University of North Carolina | Chapel Hill | North Carolina |
United States | The University of Chicago | Chicago | Illinois |
United States | University of Chicago School of Medicine | Chicago | Illinois |
United States | NorthShore University Health System | Evanston | Illinois |
United States | MedStar Georgetown University Hospital | Georgetown | District of Columbia |
United States | Yale New Haven Hospital | Hamden | Connecticut |
United States | Best Quality Research, Inc. | Hialeah | Florida |
United States | Texas Children's Hospital / Baylor College of Medicine | Houston | Texas |
United States | Indiana University School of Medicine | Indianapolis | Indiana |
United States | University of Kansas Medical Center Research Institute | Kansas City | Kansas |
United States | Valley Hospital and Medical Center | Las Vegas | Nevada |
United States | Children's Hospital of Los Angeles | Los Angeles | California |
United States | University of California | Los Angeles | California |
United States | University of Wisconsin - Madison | Madison | Wisconsin |
United States | Loyola University of Chicago/ Loyola University Medical Center | Maywood | Illinois |
United States | University of Miami, Miller School of Medicine | Miami | Florida |
United States | The Medical College of Wisconsin | Milwaukee | Wisconsin |
United States | West Virginia University | Morgantown | West Virginia |
United States | Atlantic Health System | Morristown | New Jersey |
United States | GI Pros | Naples | Florida |
United States | Vanderbilt University Medical Center | Nashville | Tennessee |
United States | Rutgers | New Brunswick | New Jersey |
United States | Ochsner | New Orleans | Louisiana |
United States | Concorde Medical Group | New York | New York |
United States | Icahn School of Medicine at Mount Sinai | New York | New York |
United States | New York University School of Medicine | New York | New York |
United States | Weill Cornell Medicine | New York | New York |
United States | Weill Cornell Medicine - Pediatric | New York | New York |
United States | Temple University | Philadelphia | Pennsylvania |
United States | Phoenix Children's Hospital | Phoenix | Arizona |
United States | Penn Medicine Princeton Health | Plainsboro | New Jersey |
United States | Oregon Health & Science University | Portland | Oregon |
United States | Brown University Women's Medicine and Collaborative | Providence | Rhode Island |
United States | Stanford University | Redwood City | California |
United States | Gastroenterology Group of Rochester, LLP | Rochester | New York |
United States | Mayo Clinic | Rochester | Minnesota |
United States | Mayo Clinic - Division of Pediatric Gastroenterology | Rochester | Minnesota |
United States | Sutter Roseville Medical Center | Roseville | California |
United States | University of California San Francisco | San Francisco | California |
United States | Baylor Research Institute - Scott & White Medical Center | Temple | Texas |
United States | Carle Foundation Hospital | Urbana | Illinois |
United States | Ventura Clinical Trials | Ventura | California |
Lead Sponsor | Collaborator |
---|---|
American Gastroenterological Association | Loyola University Chicago, OpenBiome, RX.Health Inc., University of California, San Diego, University of Minnesota, University of Pennsylvania |
United States, Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Occurrence of treatment related Adverse Events | Adverse events to be monitored include surgeries, infection, hospitalization, other life-threatening events, death and newly diagnosed diseases. | over 10 Years | |
Primary | Disease Re-occurrence Following FMT | Assess effectiveness of FMT by monitoring disease re-occurrence post treatment. | over 10 Years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02214771 -
Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These Patients
|
N/A | |
Withdrawn |
NCT01552668 -
Fidaxomicin to Prevent Clostridium Difficile Colonization
|
Phase 4 | |
Not yet recruiting |
NCT03586206 -
Relationship Between C. Difficile Toxins' Serum Level With C. Difficile Infection
|
||
Suspended |
NCT03350711 -
A Screening and Recruitment Study in Adults Expressing Interest in the Emory Microbiota Enrichment Program
|
||
Withdrawn |
NCT03643887 -
Phase II Trial of Fecal Microbiota Transplant (FMT) for VRE and CRE Patients
|
Phase 2 | |
Terminated |
NCT04000555 -
Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI)
|
Phase 4 | |
Terminated |
NCT03065374 -
Treatment for Clostridium-difficile Infection With IMM529
|
Phase 1/Phase 2 | |
Completed |
NCT03710694 -
Safety and Efficacy of DAV132 in Patients at High-Risk for Clostridium Difficile Infection (CDI)
|
N/A | |
Completed |
NCT02865616 -
MET-2 Clinical Study for Recurrent Clostridium Difficile Infection (CDI)
|
Phase 1 | |
Recruiting |
NCT04940468 -
High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology
|
N/A | |
Completed |
NCT02589847 -
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
|
Phase 2 | |
Not yet recruiting |
NCT01942447 -
Fecal Microbiota Transplantation in Recurrent or Refractory Clostridium Difficile Colitis
|
N/A | |
Active, not recruiting |
NCT02086916 -
Novel Biomarkers to Predict Outcome in Clostridium Difficile Infection
|
N/A | |
Completed |
NCT01230957 -
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
|
Phase 2 | |
Completed |
NCT01241552 -
A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)
|
Phase 3 | |
Not yet recruiting |
NCT04567134 -
Clostridioides Difficile Infection - a Prospective Nationwide Epidemiologic Study in Korea
|
||
Completed |
NCT04075422 -
Bezlotoxumab - in "Real Life" - During the First Episode of Clostridium Difficile Infection in Patients With High Risk of Recurrence.
|
||
Recruiting |
NCT03712722 -
Fecal Microbiota Transplantation (FMT) for Clostridium Difficile
|
||
Recruiting |
NCT05192148 -
Seroprevalence of Antibodies to Surface Antigens and Toxins of Clostridioides Difficile
|
N/A | |
Completed |
NCT02951702 -
Oral Vancomyin for Primary Clostridium Difficile Infection Prophylaxis in Patients Receiving High-Risk Antibiotics
|
Phase 4 |